Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

被引：76

作者：

Gerson, James N. ^{[1
]}

Handorf, Elizabeth ^{[1
]}

Villa, Diego ^{[2
]}

Gerrie, Alina S. ^{[2
]}

Chapani, Pary ^{[2
]}

Li, Shaoying ^{[3
]}

Medeiros, L. Jeffrey ^{[3
]}

Wang, Michael, I ^{[3
]}

Cohen, Jonathon B. ^{[4
]}

Calzada, Oscar ^{[4
]}

Churnetski, Michael C. ^{[4
]}

Hill, Brian T. ^{[5
]}

Sawalha, Yazeed ^{[5
]}

Hernandez-Ilizaliturri, Francisco J. ^{[6
]}

Kothari, Shalin ^{[6
]}

Vose, Julie M. ^{[7
]}

Bast, Martin A. ^{[7
]}

Fenske, Timothy S. ^{[8
]}

Gari, Swapna Narayana Rao ^{[8
]}

Maddocks, Kami J. ^{[9
]}

Bond, David ^{[9
]}

Bachanova, Veronika ^{[10
]}

Kolla, Bhaskar ^{[10
]}

Chavez, Julio ^{[11
]}

Shah, Bijal ^{[11
]}

Lansigan, Frederick ^{[12
]}

Burns, Timothy F. ^{[12
]}

Donovan, Alexandra M. ^{[12
]}

Wagner-Johnston, Nina ^{[13
]}

Messmer, Marcus ^{[13
]}

Mehta, Amitkumar ^{[14
]}

Anderson, Jennifer K. ^{[14
]}

Reddy, Nishitha ^{[15
]}

Kovach, Alexandra E. ^{[15
]}

Landsburg, Daniel J. ^{[16
]}

Glenn, Martha ^{[17
]}

Inwards, David J. ^{[18
]}

Karmali, Reem ^{[19
]}

Kaplan, Jason B. ^{[19
]}

Caimi, Paolo F. ^{[20
]}

Rajguru, Saurabh ^{[21
]}

Evens, Andrew ^{[22
]}

Klein, Andreas ^{[22
]}

Umyarova, Elvira ^{[23
]}

Pulluri, Bhargavi ^{[23
]}

Amengual, Jennifer E. ^{[24
]}

Lue, Jennifer K. ^{[24
]}

Diefenbach, Catherine ^{[25
]}

Fisher, Richard, I ^{[1
]}

Barta, Stefan K. ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] BC Canc, Vancouver, BC, Canada

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[7] Univ Nebraska, Canc Ctr, Omaha, NE 68182 USA

[8] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[9] Ohio State Univ, Columbus, OH 43210 USA

[10] Univ Minnesota, Minneapolis, MN USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[13] Johns Hopkins Univ, Baltimore, MD USA

[14] Univ Alabama Birmingham, Canc Ctr, Birmingham, AL USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Univ Penn, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[17] Huntsman Canc Inst, Salt Lake City, UT USA

[18] Mayo Clin, Rochester, MN USA

[19] Northwestern Univ, Evanston, IL USA

[20] Case Western Reserve Univ, Cleveland, OH 44106 USA

[21] Univ Wisconsin, Madison, WI USA

[22] Tufts Univ, Boston, MA 02111 USA

[23] Univ Vermont, Burlington, VT USA

[24] Columbia Univ, New York, NY USA

[25] NYU, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 06期

关键词：

PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; RANDOMIZED-TRIALS; TRANSPLANTATION; IMMUNOCHEMOTHERAPY; PATHOGENESIS; MULTICENTER; THERAPY; PATTERN; IMPACT;

D O I：

10.1200/JCO.18.00690

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEMantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.PATIENTS AND METHODSWe retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.RESULTSData were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).CONCLUSIONIn this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.

引用

页码：471 / +

页数：17

共 50 条

[1] Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era
Li, Yun
Wu, Meng
Huang, Huiqiang
Xu, Wei
Huang, Haiwen
Zhao, Weili
Wang, Yanyan
Liu, Shuo
Xu, Pengpeng
Chen, Zhengming
Song, Yuqin
Ruan, Jia
Wu, Depei
BLOOD, 2019, 134
[2] Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Karmali, Reem
Switchenko, Jeffrey M.
Goyal, Subir
Shanmugasundaram, Krithika
Churnetski, Michael C.
Kolla, Bhaskar
Bachanova, Veronika
Gerson, James N.
Barta, Stefan K.
Gordon, Max J.
Danilov, Alexey, V
Grover, Natalie S.
Epperla, Narendranath
Mathews, Stephanie
Burkart, Madelyn
Sawalha, Yazeed
Hill, Brian T.
Ghosh, Nilanjan
Park, Steven, I
Bond, David A.
Maddocks, Kami J.
Badar, Talha
Fenske, Timothy S.
Hamadani, Mehdi
Guo, Jin
Malecek, Mary
Kahl, Brad S.
Martin, Peter
Blum, Kristie A.
Flowers, Christopher R.
Cohen, Jonathon B.
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (11) : 1374 - 1384
[3] Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era
Gerson, James Nathan
Barta, Stefan Klaus
Villa, Diego
Gerrie, Alina S.
Li, Shaoying
Medeiros, Jeffrey
Wang, Michael
Hill, Brian T.
Sawalha, Yazeed
Hernandez-Ilizaliturri, Francisco J.
Kothari, Shalin
Vose, Julie M.
Fenske, Timothy S.
Rao, Swapna Narayana
Maddocks, Kami J.
Bond, David A.
Lansigan, Frederick
Burns, Timothy
Donovan, Alexandra M.
Mehta, Amitkumar
Reddy, Nishitha
Landsburg, Daniel J.
Glenn, Martha
Inwards, David James
Ristow, Kay
Karmali, Reem
Kaplan, Jason
Umyarova, Elvira
Pulluri, Bhargavi
Amengual, Jennifer E.
Lue, Jennifer Kimberly
Caimi, Paolo
Cohen, Jonathon B.
Calzada, Oscar
Handorf, Elizabeth
Anderson, Jennifer Kelly
Chapani, Parv
Bachanova, Veronika
Rajguru, Saurabh
Churnetski, Michael C.
Diefenbach, Catherine
Bast, Martin
Kovach, Alexandra E.
BLOOD, 2017, 130
[4] Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Harmanen, Minna
Hujo, Mika
Sund, Reijo
Sorigue, Marc
Khan, Madiha
Prusila, Roosa
Klaavuniemi, Tuula
Kari, Esa
Jantunen, Esa
Sunela, Kaisa
Rajamaki, Aino
Alanne, Erika
Kuitunen, Hanne
Sancho, Juan-Manuel
Jukkola, Arja
Ronka, Aino
Kuittinen, Outi
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (01) : 64 - 74
[5] Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.
Karmali, Reem
Switchenko, Jeffrey M.
Goyal, Subir
Bachanova, Veronika
Gerson, James
Barta, Stefan K.
Danilov, Alexey Valeryevich
Grover, Natalie Sophia
Epperla, Narendranath
Burkart, Madelyn
Sawalha, Yazeed
Ghosh, Nilanjan
Bond, David Alan
Maddocks, Kami J.
Badar, Talha
Fenske, Timothy
Guo, Jin
Malecek, Mary-Kate
Martin, Peter
Cohen, Jonathon Brett
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Rituximab improves survival in mantle cell lymphoma
不详
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (01) : 11 - 11
[7] Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies
Ermann, Daniel A.
Vardell, Victoria A.
Fitzgerald, Lindsey
Shah, Harsh
Bock, Allison M.
Stephens, Deborah M.
Hu, Boyu
BLOOD, 2023, 142
[8] Survival Outcomes of Rural Patients with Mantle Cell Lymphoma
Rubnitz, Zach
Vardell, Victoria A.
Fitzgerald, Lindsey
Bock, Allison M.
Shah, Harsh
Hu, Boyu
Stephens, Deborah M.
Ermann, Daniel A.
BLOOD, 2023, 142
[9] THE ROLE OF MANTLE CELL INTERNATIONAL PROGNOSTIC INDEX (MIPI) AS SURVIVAL PREDICTOR IN MANTLE CELL LYMPHOMA (MCL) PATIENTS TREATED WITH RITUXIMAB AND CHEMOTHERAPY
Chiappella, A.
Puccini, B.
Rossi, M.
Arcaini, L.
Audisio, E.
Baldi, I.
Benevolo, G.
Boccomini, C.
Botto, B.
Ciochetto, C.
Fabbri, F.
Ferrero, S.
Frairia, C.
Freilone, R.
Ladetto, M.
Novero, D.
Paulli, M.
Pregno, P.
Priolo, G.
Rigacci, L.
Vitolo, U.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 114 - 114
[10] Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era
Salek, David
Vasova, Ingrid
Pytlik, Robert
Belada, David
Papajik, Tomas
Kubackova, Katerina
Pimos, Jan
Boudova, Ludmila
Kodet, Roman
Obrtlikova, Petra
Krejcova, Hana
Tmeny, Marek
BLOOD, 2008, 112 (11) : 1283 - 1283

← 1 2 3 4 5 →